Radiation therapy and androgen deprivation in the management of high risk prostate cancer
Radiation therapy and androgen deprivation in the management of high risk prostate cancer
复制标题
DOI：
10.1590/s1677-55382011000200003
复制
发表时间：
2011-04-01
影响因子：
3.7
通讯作者：
Souhami, Luis
中科院分区：
文献类型：
--
作者：
Dal Pra, Alan;Cury, Fabio L.;Souhami, Luis
放射治疗（RT）和雄激素去势联合应用于局限性高危前列腺癌患者是泌尿肿瘤学家普遍接受的标准治疗。临床前研究为使用该组合提供了依据。此外，使用常规剂量RT的III期研究结果支持联合方法。其他3期研究也显示使用更高剂量的RT的益处;然而，雄激素剥夺在这种情况下的作用尚不清楚。在新辅助和辅助情况下，雄激素剥夺的最佳持续时间仍在研究中。本文对RT联合雄激素剥夺治疗高危前列腺癌的数据进行了批判性回顾，重点是3期试验的结果。
The combined use of radiation therapy (RT)and androgen deprivation for patients with localized high-risk prostate cancer is commonly accepted as the standard treatment among uro-oncologists. Preclinical studies have provided rationale for the use of this combination. Additionally, results of phase 3 studies using conventional doses of RT have supported the combined approach. Other phase 3 studies have also shown a benefit for using higher doses of RT; however, the role of androgen deprivation in this context is not clear. The optimal duration of the androgen deprivation, in both the neoadjuvant and adjuvant setting, is still under investigation. This article critically reviews the data on the use of RT combined with androgen deprivation for the treatment of high-risk prostate cancer with emphasis on the results of phase 3 trials.